title: Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration.
abstract: OBJECTIVE
  The aim of this study was to investigate the acute modulation of the neurotrophin Brain-derived neurotrophic factor (BDNF) by the novel antidepressant agomelatine and the relative contribution of its melatonergic and serotonergic receptor components.
  
  
  METHODS
  BDNF mRNA levels were measured in rat hippocampus and prefrontal cortex after acute administration of agomelatine, melatonin or the 5-HT(2C) antagonist S32006.
  
  
  RESULTS
  BDNF expression was significantly increased 16 h after acute agomelatine administration, an effect that follows a specific temporal profile, is limited to the prefrontal cortex and it is due to changes of specific neurotrophin transcripts. Moreover, the acute up-regulation of BDNF mRNA levels appears to be the result of a synergistic effect between the melatonergic properties of agomelatine as MT1/MT2 agonist and its serotonergic 5-HT(2C) antagonism, since either melatonin or the 5-HT(2C) antagonist S32006 does not mimic the effects of agomelatine.
  
  
  CONCLUSIONS
  These data provide evidence that acute agomelatine treatment modulates the expression of BDNF through a functional interaction between melatonergic MT1/MT2 and serotonergic 5-HT(2C) receptors, supporting the notion that intracellular events can be regulated via a synergistic activity of different neuromodulatory systems.
authors.affiliation: Center of Neuropharmacology, Department of Pharmacological Sciences, Universita' degli Studi di Milano, Milan, Italy.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Molteni
authors.forename: Francesca
authors.initials: F
authors.lastname: Calabrese
authors.forename: Sara
authors.initials: S
authors.lastname: Pisoni
authors.forename: Cecilia
authors.initials: C
authors.lastname: Gabriel
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Mocaer
authors.forename: Giorgio
authors.initials: G
authors.lastname: Racagni
authors.forename: Marco A
authors.initials: MA
authors.lastname: Riva
mesh_terms: D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000032:analysis*; D015870:Gene Expression / Q000187:drug effects; D006624:Hippocampus / Q000737:chemistry / Q000187:drug effects; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology; D008297:Male; D008550:Melatonin / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000737:chemistry* / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D044094:Receptors, Melatonin / Q000187:drug effects / Q000502:physiology; D044348:Receptors, Serotonin, 5-HT2 / Q000187:drug effects / Q000502:physiology; D012702:Serotonin Antagonists / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D019208:Brain-Derived Neurotrophic Factor; D006993:Hypnotics and Sedatives; D007211:Indoles; D008550:Melatonin; D011725:Pyridines; D012333:RNA, Messenger; D044094:Receptors, Melatonin; D044348:Receptors, Serotonin, 5-HT2; D012702:Serotonin Antagonists; C533966:S32006; C084711:agomelatine; D009281:Naphthalenes